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Background: Macrophage Migration Inhibitory Factor (MIF) has been implicated in enhancing
metastasis and increasing drug resistance in multiple types of cancer, including osteosarcoma (OS).
It trimerizes to bind to CD74 receptors. Downstream effects of this interaction enhance cell
proliferation, suppress apoptosis, and stimulate migration and angiogenesis. MIF-inhibiting
analogues have been shown to validate efficacy of MIF inhibition for treatment of bladder, colon,
prostate, and squamous cell cancers. However, the effects of these analogues in the treatment of
osteosarcoma have not been validated.
Objectives/Goal: To evaluate MIF as a viable target for the inhibition of OS cell progression with
an already validated MIF inhibitor CPSI-1306 which inhibits MIF trimerization and its analog.
Methods/Design: OS cell lines were treated with CPSI-1306 analogs. MTT viable cell proliferation
and transwell migration assays were performed using three osteosarcoma cell lines (U2OS, MG63,
and SJSA-1)
Results: Treatment of OS cell lines with two small molecule-MIF inhibitors did not show an
inhibitory effect on OS cell proliferation. However, OS cell lines treated with small molecule MIF
inhibitors showed decreased migratory potential compared to control groups, when cell migration
was stimulated with conditioned media from human macrophage-derived cells.
Conclusion and significance: Our results show small molecular MIF inhibitors decreased
migratory potential in osteosarcoma cell lines compared to control group. Thus, small molecule

MIF inhibitors have the potential to prevent migration and metastasis of OS. Metastatic OS has a 5year event free survival of less than 30%, while localized OS which is amenable to surgical
resection has better outcomes. Pharmaceutical research remains limited due to small target
market. Therefore, targeting OS cell migration and metastasis with small molecule inhibitors could
pave the road for improved treatment modalities and outcomes for OS patients.

